1871 Folsom Street
About Clovis OncologyClovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado.
April 20, 2009
Founders: Patrick Mahaffy, and Erle Mast
CEO and Co-founder: Patrick Mahaffy
CMO (Medical): Lindsey Rolfe
Please click here for Clovis Oncology job opportunities.
Please click here for clinical trial information.
265 articles with Clovis Oncology
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF)
Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019
43.9% confirmed objective response rate (ORR) in 57 RECIST*-evaluable patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1/2 mutation
Clovis Oncology, Inc. has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.
Clovis Oncology plunked down $12 million in an upfront payment to Germany-based 3B Pharmaceuticals for licensing rights to peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein alpha.
Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019
Clovis Oncology, Inc. announced that three posters highlighting studies from the Rubraca® clinical development program will be presented at the ESMO Congress 2019, September 27 – October 1, 2019, in Barcelona, Spain.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
The conference will be held at the Westin Copley Place in Boston, MA.
Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
Following the closing, there will be a total of $263.0 million aggregate principal amount of the notes outstanding.
Clovis Oncology, Inc. announced the pricing of $250 million aggregate principal amount of its 4.50% convertible senior notes due 2024 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
$33.0M in Rubraca® (rucaparib) net product revenue for Q2 2019 compared to $23.8M for Q2 2018
Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1
Clovis Oncology, Inc. will announce its second quarter 2019 financial results on Thursday, August 1, 2019, before the open of the U.S. financial markets.
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the appointment of Ginger L. Graham as Board Chair to Clovis’ Board of Directors, following the retirement of former Board Chair Dr. M. James Barrett.
Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting
Clovis Oncology, Inc. announced multiple datasets being presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 – June 4, 2019.
Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer
Quality-adjusted progression free survival (QA-PFS) and quality-adjusted time without cancer related symptoms or toxicity (Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment over placebo from a patient perspective
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2019, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year.
Clovis Oncology, Inc. announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2019 on Tuesday, May 14, 2019 at 2:20 PM Pacific Time.
Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million
Financing to fund quarterly expenses related to the ATHENA first-line maintenance clinical trial in ovarian cancer, beginning in Q2 2019 through study completion
Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7
Clovis Oncology, Inc. will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.S. financial markets.